Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-09-13
2005-09-13
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S236800, C544S128000, C544S131000, C544S133000
Reexamination Certificate
active
06943160
ABSTRACT:
This invention relates to morpholine derivatives of formula (I) and their use as antagonists of orexin receptors.
REFERENCES:
patent: 4870074 (1989-09-01), Kon et al.
patent: 4923863 (1990-05-01), Scopes et al.
patent: 5604225 (1997-02-01), Manfred et al.
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5922706 (1999-07-01), Dorn et al.
patent: 6506750 (2003-01-01), Ducoux et al.
patent: 6596730 (2003-07-01), Coulton et al.
patent: 6635661 (2003-10-01), Cuny et al.
patent: 6677332 (2004-01-01), Cuny et al.
patent: 6677354 (2004-01-01), Branch et al.
patent: 6699879 (2004-03-01), Coulton et al.
patent: 6703392 (2004-03-01), Aissaoui et al.
patent: 2004/0058923 (2004-03-01), Ancliff et al.
patent: WO 00/47577 (2000-08-01), None
patent: WO 00/47580 (2000-08-01), None
patent: WO 01/68609 (2001-09-01), None
patent: WO 2003051368 (2003-06-01), None
Voisin, T. et al., “Orexins and their receptors: structural aspects and role in peripheral tissues,” Cell Mol. Life Sci., 60: 72-87 (2003) at p. 72 1st column; 79, 1st column; and p. 84, 2nd column.
Hungs, Marcel and Mignot, Emmanuel, “Hypocretin/orexin, sleep and narcolepsy,” BioEssays 23(5): 397-408 (May 2001) at p. 398, 2nd column.
Taylor, Meghan and Shaw, Willis, “The other side of the orexins: endocrine and metabolic actions,” Am. J. Physiol. Endocrinol. Metab., 284: E13-E17 (Jan. 2003) at p. E16, 1st column.
Nishino, Seiji, et al., “Low Cerebrospinal Fluid Hypocretin (Orexin) and Altered Energy Homeostasis in Human Narcolepsy,” Ann. Neurol., 50: 381-388 (Sep. 2001) at p. 382, 1st column. PubMed ID: 11558795.
Nishino, Seiji, “The hypocretin/orexin system in health and disease,” Biol. Psychiatry, 54(2): 87-95 (Jul. 15, 2003)(abstract only).
Salomon, Ronald, et al., “Diurnal variation of cerebrospinal fluid hypocretin-1 )Orexin-A) levels in control and depressed subjects,” Biol. Psychaitry 54(2): 96-104 (Jul. 15, 2003)(abstract only). PubMed ID: 12873798.
Allen, R.P., et al., “Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome,” Neurology 59(4): 639-41 (Aug. 27, 2002)(abstract only). PubMed ID: 12196669.
Hirose, Masaaki, et al., “N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisquinoline: The first orexin-2 receptor selective non-peptidic antagonist,” Bioorganic & Medicinal Chem. Letters 13(24): 4497-4499 (Dec. 15, 2003).
Langmead, C.J., et al., “Characterization of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor,” Br. J. Pharmacol. 141(2): 340-6 (Jan. 2004)(abstract only). PubMed ID: 14691055.
Kato, Shiro, et al., “Novel benzamides as selective and potent gastrokinetic agents,” J. Med. Chem. 34(2):616-24 (1991); Reg. No. 112885-36-6.
Kato, Shiro, et al., “Synthesis and biological activity of 4-amino-5-chloro-2-ethoxy-3-hydroxybenzamides, metabolites of a new gastroprokinetic agent, mosapride,” Chem. & Pharma. Bull. 44(8):1484-1492. Reg. No. 182068004, 182068048, 182068128, 1820681511.
Cummings, Jeffrey L., “Alzheimer's Disease,” N. Engl. J. Med. 351:56-67 (Jul. 1, 2004) at pp. 56-60.
Bullock, Roger, “Future directions in the treatment of Alzheimer's disease,” Expert Opin. Invest. Drugs 13(4): 303-314 (2004) at pp. 303, 306-309.
Robinson, Stephen R., et al., “Lessons from the AN 1792 Alzheimer vaccine: lest we forget,” Neurobiol. of Aging 25(5): 609-615 (May-Jun. 2004) at pp. 609-610.
Lammers et al., “Pharmacological Management of Narcolepsy”.Expert Opin. Pharmacother., 4(10): 1739-1746 (2003).
George et al., “Hypocretin (Orexin) Pathway to Sleep”.The Lancet, 355: pp. 6 (2000).
Nishino, et al., “Hypocretin (Orexin) Deficiency in Human Narcolepsy”.The Lancet, 355: 39-40 (2000).
Samuel Klein. “The War Against Obesity: Attacking a New Front”.Am. J. Clin. Nutr., 69: 1061-1063 (1999).
Sakurai et al., “Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior”.Cell, 92: 573-585 (1998).
Branch Clive Leslie
Johnson Christopher Norbert
Smith Alexander B.
Stemp Geoffrey
Thewlis Kevin
Kinzig Charles M.
McCarthy Mary E.
Paviglianiti Anthony J.
Saeed Kamal A.
Sieburth Kathryn L.
LandOfFree
Morpholine derivatives as antagonists of orexin receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Morpholine derivatives as antagonists of orexin receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholine derivatives as antagonists of orexin receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3440728